A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3105981?pdf=render |
| _version_ | 1819010103862362112 |
|---|---|
| author | C Preston Neff Theresa Kurisu Thomas Ndolo Kami Fox Ramesh Akkina |
| author_facet | C Preston Neff Theresa Kurisu Thomas Ndolo Kami Fox Ramesh Akkina |
| author_sort | C Preston Neff |
| collection | DOAJ |
| description | For prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefore, a small animal model that facilitates rapid evaluation of potential candidates for their preliminary efficacy is urgently needed in the microbicide field. We previously demonstrated that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and rectal routes and that oral pre-exposure chemo-prophylactic strategies could be tested in this system. Here in these proof-of-concept studies, we extended this system for topical microbicide testing using HIV-1 as the challenge virus. Maraviroc, a clinically approved CCR5 inhibitor drug for HIV treatment, was formulated as a microbicide gel at 5 mM concentration in 2.2% hydroxyl ethyl cellulose. Female RAG-hu mice were challenged vaginally with HIV-1 an hour after intravaginal application of the maraviroc gel. Our results showed that maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge in contrast to placebo gel treated mice which all became infected. These findings highlight the utility of the humanized mouse models for microbicide testing and, together with the recent data from macaque studies, suggest that maraviroc is a promising candidate for future microbicide clinical trials in the field. |
| first_indexed | 2024-12-21T01:06:57Z |
| format | Article |
| id | doaj.art-881eb7cb4a204762b67e3e5ac9cbf24c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T01:06:57Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-881eb7cb4a204762b67e3e5ac9cbf24c2022-12-21T19:21:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0166e2020910.1371/journal.pone.0020209A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.C Preston NeffTheresa KurisuThomas NdoloKami FoxRamesh AkkinaFor prevention of HIV infection many currently licensed anti-HIV drugs and new ones in the pipeline show potential as topically applied microbicides. While macaque models have been the gold standard for in vivo microbicide testing, they are expensive and sufficient numbers are not available. Therefore, a small animal model that facilitates rapid evaluation of potential candidates for their preliminary efficacy is urgently needed in the microbicide field. We previously demonstrated that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and rectal routes and that oral pre-exposure chemo-prophylactic strategies could be tested in this system. Here in these proof-of-concept studies, we extended this system for topical microbicide testing using HIV-1 as the challenge virus. Maraviroc, a clinically approved CCR5 inhibitor drug for HIV treatment, was formulated as a microbicide gel at 5 mM concentration in 2.2% hydroxyl ethyl cellulose. Female RAG-hu mice were challenged vaginally with HIV-1 an hour after intravaginal application of the maraviroc gel. Our results showed that maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge in contrast to placebo gel treated mice which all became infected. These findings highlight the utility of the humanized mouse models for microbicide testing and, together with the recent data from macaque studies, suggest that maraviroc is a promising candidate for future microbicide clinical trials in the field.http://europepmc.org/articles/PMC3105981?pdf=render |
| spellingShingle | C Preston Neff Theresa Kurisu Thomas Ndolo Kami Fox Ramesh Akkina A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE |
| title | A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. |
| title_full | A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. |
| title_fullStr | A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. |
| title_full_unstemmed | A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. |
| title_short | A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. |
| title_sort | topical microbicide gel formulation of ccr5 antagonist maraviroc prevents hiv 1 vaginal transmission in humanized rag hu mice |
| url | http://europepmc.org/articles/PMC3105981?pdf=render |
| work_keys_str_mv | AT cprestonneff atopicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT theresakurisu atopicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT thomasndolo atopicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT kamifox atopicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT rameshakkina atopicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT cprestonneff topicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT theresakurisu topicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT thomasndolo topicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT kamifox topicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice AT rameshakkina topicalmicrobicidegelformulationofccr5antagonistmaravirocpreventshiv1vaginaltransmissioninhumanizedraghumice |